Certified by Founder
Lodge
AlgoTx
start up
France
- Suresnes, Ile-de-France
- 15/03/2023
- Series B
- $21,157,000
AlgoTx develops novel solutions for complex pain. Our lead program, ATX01, targets highly prevalent Chemotherapy-Induced Peripheral Neuropathy and the orphan disease erythromelalgia.
- Industry Biotechnology Research
- Website https://www.linkedin.com/company/algotx/about/
- LinkedIn https://www.linkedin.com/company/algotx/
Parhelia Biosciences | Undisclosed Amount | (Oct 18, 2023)
Cloover | $7,388,000 | (Oct 18, 2023)
Hallmark Health Care Solutions | Undisclosed Amount | (Oct 18, 2023)
Prove | $40,000,000 | (Oct 18, 2023)
Reality Defender | $15,000,000 | (Oct 18, 2023)
Yardstik | $12,000,000 | (Oct 18, 2023)
Nucleus RadioPharma | $56,000,000 | (Oct 18, 2023)
Society Brands | $25,000,000 | (Oct 18, 2023)
Nova Credit | $45,000,000 | (Oct 18, 2023)
Anonybit | $3,000,000 | (Oct 18, 2023)
Zelus Analytics | Undisclosed Amount | (Oct 18, 2023)
Scorability | $11,000,000 | (Oct 18, 2023)